Display options
Cite
Agrawal V, Christenson ES, Showel MM. Tyrosine kinase inhibitor induced isolated pericardial effusion. Case Rep Oncol. 2015;8(1):88-93doi: 10.1159/000375484.
Agrawal, V., Christenson, E. S., & Showel, M. M. (2015). Tyrosine kinase inhibitor induced isolated pericardial effusion. Case reports in oncology, 8(1), 88-93. https://doi.org/10.1159/000375484
Agrawal, Vineet, et al. "Tyrosine kinase inhibitor induced isolated pericardial effusion." Case reports in oncology vol. 8,1 (2015): 88-93. doi: https://doi.org/10.1159/000375484
Agrawal V, Christenson ES, Showel MM. Tyrosine kinase inhibitor induced isolated pericardial effusion. Case Rep Oncol. 2015 Feb 13;8(1):88-93. doi: 10.1159/000375484. eCollection 2015. PMID: 25848358; PMCID: PMC4361914.
Copy Download .nbib Format: NLM
Share it on

Case Rep Oncol. 2015 Feb 13;8(1):88-93. doi: 10.1159/000375484. eCollection 2015.

Tyrosine kinase inhibitor induced isolated pericardial effusion.

Case reports in oncology

Vineet Agrawal, Eric S Christenson, Margaret M Showel

Affiliations

  1. Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Md., USA.
  2. Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Md., USA.

PMID: 25848358 PMCID: PMC4361914 DOI: 10.1159/000375484

Abstract

Long-term therapy with tyrosine kinase inhibitors (TKI) has resulted in improved outcomes for patients suffering from Bcr-Abl fusion protein-harboring leukemias. As a result, a growing population of patients on TKI therapy present to their primary care providers. In this case, we report on the case of a 62-year-old male who presented with a symptomatic pericardial effusion. After pericardiocentesis, malignancy and infectious etiologies were excluded. The pericardial effusion was attributed to his TKI, with a transition of this medication to a different TKI. A repeat evaluation 1 month following the withdrawal of the offending agent showed no recurrence of his pericardial effusion on echocardiogram. In this report, we will highlight a rare but important side effect of TKI therapy before discussing its purported mechanisms and differing incidence rates. Early recognition of serosal inflammation related to long-term TKI therapy by primary care providers is important in preventing patient morbidity and mortality.

Keywords: Leukemia; Pericardial effusion; Tyrosine kinase inhibitor

References

  1. Cancer. 2003 May 1;97(9):2229-35 - PubMed
  2. Annu Rev Pharmacol Toxicol. 2013;53:161-85 - PubMed
  3. Target Oncol. 2009 Apr;4(2):99-105 - PubMed
  4. Cancer. 2012 Jun 15;118(12):3123-7 - PubMed
  5. Dis Mon. 2012 Apr;58(4):168-76 - PubMed
  6. Blood. 2007 Nov 15;110(10):3540-6 - PubMed
  7. Eur Heart J. 2013 Apr;34(16):1186-97 - PubMed
  8. Br J Haematol. 2008 May;141(5):745-7 - PubMed
  9. N Engl J Med. 2014 Sep 11;371(11):1005-15 - PubMed
  10. N Engl J Med. 2006 Dec 7;355(23):2408-17 - PubMed
  11. J Clin Oncol. 2007 Sep 1;25(25):3908-14 - PubMed

Publication Types